Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 19/20 | 0.51 |
| ▸ | PGR | P06401 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL189787 | 0.83 | AR (0.49) | ARPGR | |
| SCHEMBL15606510 | 0.82 | AR (0.38) | ARPGR | |
| SCHEMBL18856260 | 0.82 | AR (0.51) | ARPGR | |
| SCHEMBL4402110 | 0.82 | AR (0.51) | ARPGR | |
| SCHEMBL16130164 | 0.81 | AR (0.50) | ARPGR | |
| SCHEMBL1190703 | 0.79 | AR (0.49) | ARPGR | |
| SCHEMBL12960442 | 0.79 | AR (0.45) | ARPGR | |
| SCHEMBL22834021 | 0.78 | AR (0.47) | ARPGR | |
| SCHEMBL21936494 | 0.78 | AR (0.47) | ARPGR | |
| SCHEMBL21936738 | 0.74 | AR (0.49) | ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4310083-A1 | FURAN FUSED RING-SUBSTITUTED GLUTARIMIDE COMPOUND | Medshine Discovery Inc. (CN) | 2024-01-24 | — | — | EP | disclosed |
| EP-2963026-B1 | SUBSTITUTED (R)-3-(4-METHYLCARBAMOYL-3-FLUOROPHENYLAMINO)TETRAHYDROFURAN-3-ENECARBOXYLIC ACID (VARIANTS) AND ESTER THEREOF, METHOD FOR PRODUCING AND USING SAME | R PHARM INT LLC (RU) | 2020-04-29 | — | — | EP | disclosed |
| EP-3303300-B1 | PROCESS FOR THE PREPARATION OF ENZALUTAMIDE | OLON SPA (IT) | 2020-03-25 | — | — | EP | disclosed |
| US-10035776-B2 | Process for the preparation of enzalutamide | OLON S.P.A. (IT) | 2018-07-31 | — | — | US | disclosed |
| US-20180148416-A1 | INDUSTRIAL PROCESS FOR THE PREPARATION OF ENZALUTAMIDE | OLON S.P.A. (IT) | 2018-05-31 | — | — | US | disclosed |
| US-20180141914-A1 | PROCESS FOR THE PREPARATION OF ENZALUTAMIDE | OLON S.P.A. (IT) | 2018-05-24 | — | — | US | disclosed |
| WO-2017081702-A2 | A PROCESS FOR PREPARATION OF ENZALUTAMIDE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-05-18 | — | — | WO | disclosed |
| US-20160022642-A1 | Compounds Useful for Promoting Protein Degradation and Methods Using Same | YALE UNIVERSITY | 2016-01-28 | — | — | US | disclosed |
| US-20160016925-A1 | Substituted (R)-3-(4-methylcarbamoyl-3-fluorophenylamino)tetrahydrofuran-3-encarboxylic acid (variants) and ester thereof, method for preparation and use | Ivachtchenko, Alexandre Vasilievich (US) | 2016-01-21 | — | — | US | disclosed |
| US-20150119435-A1 | COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME | YALE UNIVERSITY | 2015-04-30 | — | — | US | disclosed |
| WO-2015018356-A1 | DIARYLHYDANTOIN DERIVATIVE, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | 上海医药集团股份有限公司 (CN) | 2015-02-12 | — | — | WO | disclosed |
| WO-2013170147-A1 | COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME | YALE UNIVERSITY (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20120251551-A1 | Substituted (Heteroarylmethyl)thiohydantoins | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-04 | — | — | US | disclosed |
| US-8168667-B2 | Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such | GALAPAGOS NV (BE) | 2012-05-01 | — | — | US | disclosed |
| EP-1893196-B1 | DIARYLHYDANTOIN COMPOUND | UNIV CALIFORNIA (US) | 2012-01-18 | — | — | EP | disclosed |
| US-20100210699-A1 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | DART THERAPUTICS, LLC. | 2010-08-19 | — | — | US | disclosed |
| US-20100063120-A1 | Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such | SASU, GALAPAGOS (FR) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119435-A1 | COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME | PSMG3, ERAP1, SMURF2 | AR 2004/4885PGR 3799/4885 |
| US-20120251551-A1 | Substituted (Heteroarylmethyl)thiohydantoins | TPMT, BPHL, VHL | AR 58/4885PGR 1590/4885 |
| US-20160016925-A1 | Substituted (R)-3-(4-methylcarbamoyl-3-fluorophenylamino)tetrahydrofuran-3-encarboxylic acid (variants) and ester thereof, method for preparation and use | AR, SRD5A1, CYP19A1 | AR 1/4885PGR 263/4885 |
| US-20180148416-A1 | INDUSTRIAL PROCESS FOR THE PREPARATION OF ENZALUTAMIDE | AR, HDAC11, HDAC1 | AR 1/4885PGR 2472/4885 |
| US-20100210699-A1 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | NR5A1, AR, HSD17B7 | AR 2/4885PGR 355/4885 |
| US-20160022642-A1 | Compounds Useful for Promoting Protein Degradation and Methods Using Same | AR, SHBG, PSMG3 | AR 1/4885PGR 520/4885 |
| US-10035776-B2 | Process for the preparation of enzalutamide | AR, CYP19A1, CYP17A1 | AR 1/4885PGR 152/4885 |
| US-20180141914-A1 | PROCESS FOR THE PREPARATION OF ENZALUTAMIDE | AR, CYP19A1, CYP17A1 | AR 1/4885PGR 152/4885 |
| US-20100063120-A1 | Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such | NR5A1, AR, HSD17B7 | AR 2/4885PGR 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.